Madrigal Pharmaceuticals (LTS:0JXI) Cyclically Adjusted Book per Share: $22.64 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JXI Madrigal Pharmaceuticals Inc LTS:0JXI
28 GF Score
Price $544.11
! 5 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Cyclically Adjusted Book per Share?

Madrigal Pharmaceuticals LTS:0JXI -0.11% 28 Cyclically Adjusted Book per Share is $22.64 as of Mar. 2026. GuruFocus rates LTS:0JXI with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Madrigal Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $23.585. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $22.64 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Madrigal Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 11.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 1.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Madrigal Pharmaceuticals was 35.50% per year. The lowest was -23.90% per year. And the median was 0.65% per year.

As of today (2026-07-25), Madrigal Pharmaceuticals's current stock price is $544.11. Madrigal Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $22.64. Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 24.03.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Madrigal Pharmaceuticals was 29.16. The lowest was 10.88. And the median was 17.66.


Madrigal Pharmaceuticals  (LTS:0JXI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=544.11/22.64
=24.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Madrigal Pharmaceuticals was 29.16. The lowest was 10.88. And the median was 17.66.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Madrigal Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Madrigal Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Madrigal Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals Cyclically Adjusted Book per Share Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.13 19.47 17.98 19.72 21.81

Madrigal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.29 20.27 19.96 21.81 22.64

LTS:0JXI vs BMRN, AXSM, CYTK: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0JXI
28GF Score
Madrigal Pharmaceuticals Inc LTS:0JXI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Madrigal Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=23.585/330.2130*330.2130
=23.585

Current CPI (Mar. 2026) = 330.2130.

Madrigal Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 10.560 241.018 14.468
201609 3.249 241.428 4.444
201612 3.046 241.432 4.166
201703 2.832 243.801 3.836
201706 4.932 244.955 6.649
201709 4.346 246.819 5.814
201712 12.810 246.524 17.159
201803 12.433 249.554 16.452
201806 31.636 251.989 41.457
201809 31.372 252.439 41.037
201812 30.955 251.233 40.686
201903 30.389 254.202 39.476
201906 29.624 256.143 38.191
201909 28.540 256.759 36.705
201912 26.999 256.974 34.694
202003 24.984 258.115 31.963
202006 22.212 257.797 28.451
202009 18.732 260.280 23.765
202012 15.474 260.474 19.617
202103 16.221 264.877 20.222
202106 16.304 271.696 19.816
202109 13.931 274.310 16.770
202112 11.466 278.802 13.580
202203 8.522 287.504 9.788
202206 4.884 296.311 5.443
202209 0.624 296.808 0.694
202212 10.904 296.797 12.132
202303 8.212 301.836 8.984
202306 5.607 305.109 6.068
202309 1.203 307.789 1.291
202312 20.394 306.746 21.954
202403 41.129 312.332 43.484
202406 39.497 314.175 41.513
202409 35.640 315.301 37.326
202412 34.282 315.605 35.869
202503 32.028 319.799 33.071
202506 31.321 322.561 32.064
202509 27.560 324.800 28.019
202512 26.385 324.054 26.886
202603 23.585 330.213 23.585

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $22.64 mean?
Madrigal Pharmaceuticals (LTS:0JXI) has a Cyclically Adjusted Book per Share of $22.64 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Madrigal Pharmaceuticals and its competitors.
Is Madrigal Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Madrigal Pharmaceuticals' current Cyclically Adjusted Book per Share is $22.64. Overall, Madrigal Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Cyclically Adjusted Book per Share compare to BMRN and AXSM?
Madrigal Pharmaceuticals' Cyclically Adjusted Book per Share of $22.64 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Cyclically Adjusted Book per Share is $22.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (LTS:0JXI) has a current Cyclically Adjusted Book per Share of $22.64. The current Cyclically Adjusted Book per Share is $22.64. Madrigal Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Madrigal Pharmaceuticals (LTS:0JXI), the current Cyclically Adjusted Book per Share is $22.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
28GF Score

Get the complete analysis for LTS:0JXI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$544.11
Price